Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J P Adler-Moore

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|April 24, 2008
Amphotericin B lipid preparations: what are the differences?J P Adler-Moore, R T Proffitt
Antimicrobial Agents and Chemotherapy|August 22, 2000
Single-dose AmBisome (Liposomal amphotericin B) as prophylaxis for murine systemic candidiasis and histoplasmosisA Garcia, J P Adler-Moore, R T Proffitt
Medical Mycology|February 10, 2010
Differences in tissue drug concentrations following intravenous versus intraperitoneal treatment with amphotericin B deoxycholate or liposomal amphotericin BT Chang, J A Olson, R T Proffitt, et al.
Medical Mycology|October 20, 1998
Antimicrobial activity of AmBisome and non-liposomal amphotericin B following uptake of Candida glabrata by murine epidermal Langerhans cellsP J Sperry, D J Cua, S A Wetzel, et al.
Journal of Liposome Research|May 9, 2017
Tissue pharmacokinetics and pharmacodynamics of AmBisome® (L-AmBis) in uninfected and infected animals and their effects on dosing regimensJ P Adler-Moore, R T Proffitt, J A Olson, et al.
The Journal of Antimicrobial Chemotherapy|October 1, 1991
Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodentsR T Proffitt, A Satorius, S M Chiang, et al.
Vaccine|October 20, 2009
Liposomal gD ectodomain (gD1-306) vaccine protects against HSV2 genital or rectal infection of female and male miceK Olson, P Macias, S Hutton, et al.
Antimicrobial Agents and Chemotherapy|October 5, 2011
Differences in efficacy and cytokine profiles following echinocandin or liposomal amphotericin B monotherapy or combination therapy for murine pulmonary or systemic Aspergillus flavus infectionsJ A Olson, J Schwartz, D Hahka, et al.
Journal of Liposome Research|September 19, 2017
Monomeric M2e antigen in VesiVax<sup>®</sup> liposomes stimulates protection against type a strains of influenza comparable to liposomes with multimeric forms of M2eJ P Adler-Moore, W Ernst, H Kim, et al.
Medical Mycology|January 1, 2015
Toxicity and efficacy differences between liposomal amphotericin B formulations in uninfected and Aspergillus fumigatus infected miceJ A Olson, J A Schwartz, D Hahka, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|April 24, 2008
Amphotericin B lipid preparations: what are the differences?J P Adler-Moore, R T Proffitt
Antimicrobial Agents and Chemotherapy|August 22, 2000
Single-dose AmBisome (Liposomal amphotericin B) as prophylaxis for murine systemic candidiasis and histoplasmosisA Garcia, J P Adler-Moore, R T Proffitt
Medical Mycology|February 10, 2010
Differences in tissue drug concentrations following intravenous versus intraperitoneal treatment with amphotericin B deoxycholate or liposomal amphotericin BT Chang, J A Olson, R T Proffitt, et al.
Medical Mycology|October 20, 1998
Antimicrobial activity of AmBisome and non-liposomal amphotericin B following uptake of Candida glabrata by murine epidermal Langerhans cellsP J Sperry, D J Cua, S A Wetzel, et al.
Journal of Liposome Research|May 9, 2017
Tissue pharmacokinetics and pharmacodynamics of AmBisome® (L-AmBis) in uninfected and infected animals and their effects on dosing regimensJ P Adler-Moore, R T Proffitt, J A Olson, et al.
The Journal of Antimicrobial Chemotherapy|October 1, 1991
Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodentsR T Proffitt, A Satorius, S M Chiang, et al.
Vaccine|October 20, 2009
Liposomal gD ectodomain (gD1-306) vaccine protects against HSV2 genital or rectal infection of female and male miceK Olson, P Macias, S Hutton, et al.
Antimicrobial Agents and Chemotherapy|October 5, 2011
Differences in efficacy and cytokine profiles following echinocandin or liposomal amphotericin B monotherapy or combination therapy for murine pulmonary or systemic Aspergillus flavus infectionsJ A Olson, J Schwartz, D Hahka, et al.
Journal of Liposome Research|September 19, 2017
Monomeric M2e antigen in VesiVax<sup>®</sup> liposomes stimulates protection against type a strains of influenza comparable to liposomes with multimeric forms of M2eJ P Adler-Moore, W Ernst, H Kim, et al.
Medical Mycology|January 1, 2015
Toxicity and efficacy differences between liposomal amphotericin B formulations in uninfected and Aspergillus fumigatus infected miceJ A Olson, J A Schwartz, D Hahka, et al.
Pageof 2